Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018)

Anaptysbio (ANAB) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $171000.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Non-Current Deffered Revenue rose 22.14% year-over-year to $171000.0, compared with a TTM value of $171000.0 through Dec 2018, up 22.14%, and an annual FY2018 reading of $171000.0, up 22.14% over the prior year.
  • Non-Current Deffered Revenue was $171000.0 for Q4 2018 at Anaptysbio, up from $162000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $171000.0 in Q4 2018 and bottomed at $128000.0 in Q2 2018.
  • Average Non-Current Deffered Revenue over 3 years is $151555.6, with a median of $154000.0 recorded in 2016.
  • Peak annual rise in Non-Current Deffered Revenue hit 22.14% in 2018, while the deepest fall reached 23.81% in 2018.
  • Year by year, Non-Current Deffered Revenue stood at $154000.0 in 2016, then fell by 9.09% to $140000.0 in 2017, then rose by 22.14% to $171000.0 in 2018.
  • Business Quant data shows Non-Current Deffered Revenue for ANAB at $171000.0 in Q4 2018, $162000.0 in Q3 2018, and $128000.0 in Q2 2018.